These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32995252)

  • 1. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group.
    Brown JE; Handforth C; Compston JE; Cross W; Parr N; Selby P; Wood S; Drudge-Coates L; Walsh JS; Mitchell C; Collinson FJ; Coleman RE; James N; Francis R; Reid DM; McCloskey E
    J Bone Oncol; 2020 Dec; 25():100311. PubMed ID: 32995252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving bone health in prostate cancer patients starting androgen deprivation therapy: does Fracture Risk Assessment Tool (FRAX®) enhance stratification and targeted management?
    Sharqawi A; Hewitt K; Alexander C; El-Sakka AI; Lee L
    Arch Osteoporos; 2022 Nov; 17(1):143. PubMed ID: 36376762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: A comprehensive review.
    Sharma A; Sinha RJ; Singh V; Garg G; Agarwal S; Pandey S
    Turk J Urol; 2019 Jul; 45(4):245-253. PubMed ID: 30817274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
    Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
    Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective longitudinal study to evaluate bone health, implication of FRAX tool and impact on quality of life (FACT-P) in advanced prostate cancer patients.
    Sharma A; Garg G; Sadasukhi N; Sadasukhi TC; Gupta HL; Gupta M; Malik S; Patel K; Sinha RJ
    Am J Clin Exp Urol; 2021; 9(3):211-220. PubMed ID: 34327260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.
    Kanis JA; Harvey NC; Cooper C; Johansson H; Odén A; McCloskey EV;
    Arch Osteoporos; 2016 Dec; 11(1):25. PubMed ID: 27465509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy.
    Casado E; Borque-Fernando A; Caamaño M; Graña J; Muñoz-Rodríguez J; Morote J
    World J Mens Health; 2022 Jan; 40(1):74-86. PubMed ID: 34983087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of the Brazilian Fracture Assessment Risk Tool (FRAX) model and the age-dependent intervention thresholds according to National Osteoporosis Guideline Group (NOGG) guidelines on fracture prediction in community-dwelling older adults: the São Paulo Ageing and Health (SPAH) Study.
    Freitas TQ; Olalla LFG; Machado LG; Figueiredo CP; Takayama L; de Falco Caparbo V; Domiciano DS; Pereira RMR
    Arch Osteoporos; 2024 Jul; 19(1):59. PubMed ID: 38990403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX.
    Adler RA; Hastings FW; Petkov VI
    Osteoporos Int; 2010 Apr; 21(4):647-53. PubMed ID: 19533207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group (NOGG) guidance in the UK-an analysis of anonymous website activity.
    McCloskey EV; Johansson H; Harvey NC; Compston J; Kanis JA
    Osteoporos Int; 2017 Jan; 28(1):71-76. PubMed ID: 27438128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinician's guide to prevention and treatment of osteoporosis.
    LeBoff MS; Greenspan SL; Insogna KL; Lewiecki EM; Saag KG; Singer AJ; Siris ES
    Osteoporos Int; 2022 Oct; 33(10):2049-2102. PubMed ID: 35478046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of vitamin D in relation to bone health.
    Cranney A; Horsley T; O'Donnell S; Weiler H; Puil L; Ooi D; Atkinson S; Ward L; Moher D; Hanley D; Fang M; Yazdi F; Garritty C; Sampson M; Barrowman N; Tsertsvadze A; Mamaladze V
    Evid Rep Technol Assess (Full Rep); 2007 Aug; (158):1-235. PubMed ID: 18088161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of care provided to prostate cancer (PC) patients for prevention and treatment of osteoporosis induced by androgen deprivation therapy (ADT).
    Chahin R; Gulamhusein H; Breunis H; Alibhai SM
    Support Care Cancer; 2016 Nov; 24(11):4713-20. PubMed ID: 27370648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of bone loss in men with prostate cancer.
    Higano CS
    J Urol; 2003 Dec; 170(6 Pt 2):S59-63; discussion S64. PubMed ID: 14610412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy.
    James H; Aleksic I; Bienz MN; Pieczonka C; Iannotta P; Albala D; Mariados N; Mouraviev V; Saad F
    Urology; 2014 Jul; 84(1):164-8. PubMed ID: 24976229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.